Alk-Abello AS (STU:4AJ0) Total Liabilities : €284.9 Mil (As of Jun. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Alk-Abello AS Total Liabilities?

Alk-Abello AS's Total Liabilities for the quarter that ended in Jun. 2024 was €284.9 Mil.

Alk-Abello AS's quarterly Total Liabilities declined from Dec. 2023 (€305.77 Mil) to Mar. 2024 (€280.84 Mil) but then increased from Mar. 2024 (€280.84 Mil) to Jun. 2024 (€284.85 Mil).

Alk-Abello AS's annual Total Liabilities declined from Dec. 2021 (€316.02 Mil) to Dec. 2022 (€311.85 Mil) and declined from Dec. 2022 (€311.85 Mil) to Dec. 2023 (€305.77 Mil).

Alk-Abello AS Total Liabilities Historical Data

The historical data trend for Alk-Abello AS's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alk-Abello AS Total Liabilities Chart

Alk-Abello AS Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

310.45

323.94

316.02

311.85

305.77

Alk-Abello AS Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Total Liabilities	Get a 7-Day Free Trial															305.30	298.63	305.77	280.84	284.85

Alk-Abello AS Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Alk-Abello AS's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	176.295	+	(58.899	+	37.7
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	32.871)
	=	305.8

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	902.403	-	596.638
	=	305.8

Alk-Abello AS's Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	154.619	+	(59.221	+	37.651
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	33.362)
	=	284.9

Total Liabilities	=	Total Assets (Q: Jun. 2024 )	-	Total Equity (Q: Jun. 2024 )
	=	943.926	-	659.073
	=	284.9

Alk-Abello AS Total Liabilities Related Terms

Thank you for viewing the detailed overview of Alk-Abello AS's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Alk-Abello AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alk-Abello AS (STU:4AJ0) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

AKBLF:USA 0OIR:UK ALK B:Denmark 4AJ0:Germany

Address

Boge Alle 6-8, Horsholm, DNK, DK-2970

Website

https://www.alk.net

Alk-Abello A/S is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication.

Alk-Abello AS Headlines

No Headlines